The affected products include:
- Forty-two lots of 8.4 percent sodium bicarbonate injection 50 mL vials
- Five lots of NeutTM 5 mL vials
- Five lots of QuelicinTM 10 mL vials
- Seven lots of potassium phosphates injection 45 mM vials
The recall comes after a routine simulation of the manufacturing process uncovered the potential for microbial growth, meaning microorganisms may be in the products. However, microorganisms have not been detected in actual batches of the solutions, and no adverse events have been reported to Hospira.
Organizations with any of the affected products should stop use and quarantine them immediately, according to the recall notice.
See the full recall notice, posted by the Food and Drug Administration, here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
